How will immunotherapy change the multidisciplinary management of urothelial bladder cancer?
ESU Course 35

**Location:** Green Area, Room 15

**Chair:** A. Necchi, Milan (IT)

Voting will be available via the EAU19 App or via www.qna.at/eau

**Aims and objectives of this session**
Results obtained from large immunotherapy trials paved the way of a revolutionary road in the treatment of locally advanced and metastatic urothelial bladder cancer (UBC). For clear-cell renal cell carcinoma (RCC), use of immunotherapy combinations (with either other immune checkpoint inhibitors or targeted therapy/antiangiogenic drugs) resulted in a shifting paradigm for the first-line therapy of advanced disease. For both of these tumors, developments of immunotherapy trials in earlier disease stages are progressing at an impressively quick step. Therefore, as never before, there is a need for updates on the multidisciplinary management of these patients.

In brief, the aims of the course will be the following:
- To provide urologists with the state-of-the art on the use of immune-checkpoint inhibitors in UBC and RCC.
- To provide urologists with an overview of the ongoing clinical trials throughout the clinical stages, with a special focus on perioperative stages.
- To discuss the optimal clinical management of patients with UBC or RCC receiving immune checkpoint inhibitor treatment, including the management of side effects.

**Background - State-of-the art and ongoing developments**
A. Necchi, Milan (IT)

**Clinical cases discussion**
J. Bedke, Tübingen (DE)

**Immune checkpoint inhibitors in the perioperative setting of urothelial cancer:**

**Immune checkpoint inhibitors and the multidisciplinary management of locally advanced bladder cancer:**

**Background**
A. Necchi, Milan (IT)

**Case discussion 1 – optimal approach for cisplatin - ineligible patients**
J. Bedke, Tübingen (DE)

**Case discussion 2 – therapeutic sequences for platinum - refractory patients**
A. Necchi, Milan (IT)
| Case discussion 3 - Management of adverse events: What urologists should know |
| J. Bedke, Tübingen (DE) |

Management of RCC in the perioperative setting:

**Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy**
A. Bex, Amsterdam (NL)

**Neoadjuvant and adjuvant immunotherapy developments**
J. Bedke, Tübingen (DE)

Immune checkpoint inhibitors and the multidisciplinary management of locally-advanced renal cell cancer:

**Benchmark of immunotherapy - based results**
A. Necchi, Milan (IT)

**Case discussion 2 – role of tyrosine-kinase inhibitors in advanced RCC**
J. Bedke, Tübingen (DE)

**Case discussion 3 – development of first-line immune - oncology combinations**
A. Bex, Amsterdam (NL)

**Case discussion 1 – combination immunotherapy as first line therapy of advanced RCC**
A. Bex, Amsterdam (NL)

**Conclusion**
A. Necchi, Milan (IT)